Press Release

Kent Walker Joins HeartFlow Board of Directors

REDWOOD CITY, Calif. – March 3, 2015 – HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, has appointed Kent Walker as the newest member of its board of directors. Walker, senior vice president and general counsel at Google, brings extensive knowledge of global technology legal matters, including security and privacy, and corporate governance.

“Kent’s knowledge of the business and legal environment will be of tremendous benefit to HeartFlow, especially as we continue to expand our reach and commercialize the HeartFlow FFRCT® Analysis,” said John H. Stevens, M.D., chairman and CEO of HeartFlow. “His understanding of how to scale large technology companies, while also maintaining data security and privacy, makes him the ideal addition to the board of directors, and we are pleased to incorporate his extensive experience to our board.”

As Google’s general counsel, Walker leads the company’s global legal team and advises its board and management on legal issues and corporate governance matters. Prior to joining Google, Walker held senior legal positions at a number of leading technology companies, including deputy general counsel at eBay Inc., associate general counsel at Netscape and America Online, and senior counsel for AirTouch Communications. Walker started his career as an assistant U.S. attorney with the United States Department of Justice, where he specialized in prosecution of technology crimes and advised the attorney general on management and technology issues.

“HeartFlow has been able to develop and apply advanced technology in a dramatic new way, tackling one of today’s leading health issues,” Walker said. “I look forward to the opportunity to help the organization grow around the world.”

Walker graduated from Harvard College with a bachelor’s degree in social studies, and received his juris doctorate from Stanford Law School. He also serves on the advisory boards of the Harvard School of Public Health and Mercy Corps Social Ventures Fund.

About HeartFlow Inc.

HeartFlow Inc. is a personalized medical technology company dedicated to transforming the way cardiovascular disease is managed. Committed to improving outcomes, reducing costs and creating a better patient experience, HeartFlow’s goal is to provide healthcare professionals with actionable knowledge about each patient by combining best-in-class, non-invasive healthcare imaging with advanced, computational fluid dynamics technology and the insights of big data. Its non-invasive HeartFlow FFRCT Analysis helps physicians diagnose coronary artery disease and provides them with information they need to manage each patient. For more information visit

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.